Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03DAP
|
|||
| Former ID |
DAP000518
|
|||
| Drug Name |
Flecainide
|
|||
| Synonyms |
flecainide; 54143-55-4; Flecaine; Tambocor; Flecainida; Flecainidum; (+-)-Flecainide; Flecainidum [INN-Latin]; Flecainida [INN-Spanish]; N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; Flecainide [INN:BAN]; CCRIS 313; Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-; C17H20F6N2O3; CHEMBL652; N-(2-Piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide; CHEBI:75984; DJBNUMBKLMJRSA-UHFFFAOYSA-N; NCGC00015443-06; DSSTox_CID_3054; DSSTox_RID_76854; DSSTox_GSID_23054; (-)-Flecainide; Flecaine; Almarytm (TN); Apocard (TN); Ecrinal (TN); Flecainide (INN); Tambocor (TN); N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide; Ic Flecainide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Tachyarrhythmias [ICD-11: BC71; ICD-10: I49, I49.8] | Approved | [1], [2] | |
| Paroxysmal atrial fibrillation [ICD-11: BC81.30; ICD-10: I48.0; ICD-9: 427.31] | Phase 1 | [3] | ||
| Atrial fibrillation [ICD-11: BC81.3; ICD-10: I48] | Investigative | [4] | ||
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Company |
3M pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H20F6N2O3
|
|||
| Canonical SMILES |
C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F
|
|||
| InChI |
1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)
|
|||
| InChIKey |
DJBNUMBKLMJRSA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 54143-55-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9214, 534983, 6136451, 7979229, 8152135, 11120255, 11120743, 11121231, 11121382, 11121862, 11362451, 11365013, 11367575, 11370173, 11370174, 11373176, 11375737, 11466763, 11467883, 11486365, 14879920, 26752195, 26752196, 29222491, 46508078, 47216560, 47216561, 47440010, 47515100, 47588785, 47736232, 47810528, 47959497, 48258984, 48416013, 49699155, 49877342, 50104858, 50104859, 50484619, 53787709, 57321748, 85202322, 85787715, 85788502, 92308773, 92309733, 92714655, 96024657, 99300647
|
|||
| ChEBI ID |
CHEBI:75984
|
|||
| ADReCS Drug ID | BADD_D00902 ; BADD_D00903 | |||
| SuperDrug ATC ID |
C01BC04
|
|||
| SuperDrug CAS ID |
cas=054143554
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel (Nav) | Target Info | Modulator | [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2560). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075442. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. | |||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.